Artelo Biosciences Q1 net loss widens, R&D expenses fall

Artelo Biosciences

14/05/2026 21:23

Overview

U.S. clinical-stage pharma firm's Q1 net loss widened to $3.0 mln from $2.4 mln

R&D expenses fell while G&A expenses increased compared to prior year

Company highlighted clinical progress for ART26.12 and ART27.13 programs

Outlook

Company expects to begin multiple ascending dose study of ART26.12 in Q4 2026

Company plans to initiate Phase 1 clinical studies of ART12.11 in H1 2026

Company says recent capital raise provides significant cash runway to advance clinical programs

Result Drivers

R&D SPENDING DECLINE - Q1 R&D expenses fell to $0.8 mln from $1.4 mln a year earlier, with no specific reason given for the decrease

HIGHER G&A EXPENSES - Q1 general and administrative expenses rose to $1.9 mln from $1.0 mln a year earlier, with no detailed explanation provided

Company press release: ID:nGNX5wmqWx

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$3 mln


Analyst Coverage

The one available analyst rating on the shares is "hold"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)